Lung cancer immunotherapy adjuvant and neoadjuvant indications
Lung cancer immunotherapy adjuvant and neoadjuvant indications
Study shows that there is slower cancer drug approval in Europe
War in Ukraine: Global cancer aid to support refugees
War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis
ASCO and WHO to collaborate on quality indicators for cancer facilities
Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM
Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma
Quizartinib advances overall survival in acute myeloid leukaemia patients
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma